Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is 143.79% higher on its value in year-to-date trading and has touched a low of $3.04 and a high of $30.98 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RYTM stock was last observed hovering at around $24.08 in the last trading session, with the day’s gains setting it 0.25% off its average median price target of $28.00 for the next 12 months. It is also 39.18% off the consensus price target high of $40.00 offered by 8 analysts, but current levels are -52.06% lower than the price target low of $16.00 for the same period.
Currently trading at $24.33, the stock is 1.33% and 24.63% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.79 million and changing 1.04% at the moment leaves the stock 132.07% off its SMA200. RYTM registered 93.56% gain for a year compared to 6-month gain of 110.10%.
The stock witnessed a 3.22% loss in the last 1 month and extending the period to 3 months gives it a 410.06%, and is -21.13% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.54% over the week and 12.57% over the month.
Rhythm Pharmaceuticals Inc. (RYTM) has around 140 employees, a market worth around $1.19B and $13.40M in sales. Distance from 52-week low is 700.33% and -21.47% from its 52-week high. The company has generated returns on investments over the last 12 months (-59.80%).
Rhythm Pharmaceuticals Inc. (RYTM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Rhythm Pharmaceuticals Inc. (RYTM) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 1.90, where 2 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Rhythm Pharmaceuticals Inc. is expected to release its quarterly report on 11/09/2022.The EPS is expected to grow by 53.80% this year
Rhythm Pharmaceuticals Inc. (RYTM) Top Institutional Holders
The shares outstanding are 50.40M, and float is at 36.05M with Short Float at 16.11%.
Rhythm Pharmaceuticals Inc. (RYTM) Insider Activity
A total of 8 insider transactions have happened at Rhythm Pharmaceuticals Inc. (RYTM) in the last six months, with sales accounting for 4 and purchases happening 4 times. The most recent transaction is an insider sale by Cramer Pamela J., the company’s Chief Human Resources Officer. SEC filings show that Cramer Pamela J. sold 13,493 shares of the company’s common stock on Aug 19 at a price of $24.83 per share for a total of $0.34 million. Following the sale, the insider now owns 2224.0 shares.
Rhythm Pharmaceuticals Inc. disclosed in a document filed with the SEC on Jul 27 that Cramer Pamela J. (Chief Human Resources Officer) sold a total of 901 shares of the company’s common stock. The trade occurred on Jul 27 and was made at $11.68 per share for $10524.0. Following the transaction, the insider now directly holds 2224.0 shares of the RYTM stock.
Still, SEC filings show that on Jul 01, Smith Hunter C (Chief Financial Officer) disposed off 7,547 shares at an average price of $4.08 for $30792.0. The insider now directly holds 57,614 shares of Rhythm Pharmaceuticals Inc. (RYTM).
Rhythm Pharmaceuticals Inc. (RYTM): Who are the competitors?
The company’s main competitors (and peers) include Medtronic plc (MDT) that is -32.94% lower over the past 12 months. Stryker Corporation (SYK) is -20.79% down on the 1-year trading charts.